Evidence map›Paper›PMID 28292326›Full record

ReviewChinese journal of cancer2017

Immune mediators in the tumor microenvironment of prostate cancer.

Jinlu Dai, Yi Lu, Hernan Roca, Jill M Keller, Jian Zhang, Laurie K McCauley, Evan T Keller

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chinese journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06056791 (An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy), which is not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06056791 phase1 / phase2completednot on this mapstarted 2023, after this paper: background citation

An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

TypeinterventionalSponsorInmune Bio, Inc.Ran2023 to 2025Enrolled12ConditionsCancer, Metastatic Castration-resistant Prostate Cancer, mCRPCArmsINKmune
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Human Group IIA Secreted Phospholipase AInternational journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Metabolic changes during prostate cancer development and progression.Journal of cancer research and clinical oncology · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jinlu DaiDepartment of Urology and Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA.
Yi LuCenter for Translational Medicine, Guangxi Medical University, Nanning, Guangxi, 520021, P. R. China.
Hernan RocaPeriodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, 48109, USA.
Jill M KellerDepartment of Urology and Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA.
Jian ZhangCenter for Translational Medicine, Guangxi Medical University, Nanning, Guangxi, 520021, P. R. China.
Laurie K McCauleyPeriodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, 48109, USA.
Evan T KellerDepartment of Urology and Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA. etkeller@umich.edu.
University of Michigan–Ann Arbor · USGuangxi Medical University · CNBioSurfaces (United States) · US

Funding

Tumor microvesicle-mediated modulation of the bone microenvironmentP01CA093900 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KELLER, EVAN T · 2004 to 2024
$29.6M
Osteocytes in prostate cancer bone metastasisR01CA190554 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KELLER, EVAN T · 2015 to 2019
$1.8M
NCI NIH HHS P01 CA093900NCI NIH HHS R01 CA190554
6 · The paper itself

Abstract

Prostate cancer tissue is composed of both cancer cells and host cells. The milieu of host components that compose the tumor is termed the tumor microenvironment (TME). Host cells can be those derived from the tissue in which the tumor originates (e.g., fibroblasts and endothelial cells) or those recruited, through chemotactic or other factors, to the tumor (e.g., circulating immune cells). Some immune cells are key players in the TME and represent a large proportion of non-tumor cells found within the tumor. Immune cells can have both anti-tumor and pro-tumor activity. In addition, crosstalk between prostate cancer cells and immune cells affects immune cell functions. In this review, we focus on immune cells and cytokines that contribute to tumor progression. We discuss T-regulatory and T helper 17 cells and macrophages as key modulators in prostate cancer progression. In addition, we discuss the roles of interleukin-6 and receptor activator of nuclear factor kappa-B ligand in modulating prostate cancer progression. This review highlights the concept that immune cells and cytokines offer a potentially promising target for prostate cancer therapy.

Indexed as

AnimalsCytokinesHumansMaleProstatic NeoplasmsRANK LigandTumor MicroenvironmentCytokinesRANK LigandInterleukin-6MacrophageProstate cancerReceptor activator of nuclear factor kappa-B ligandTh17 cellT-regulatory cellTumor microenvironment

Identifiers

PMID28292326
PMCPMC5351274
OpenAlexW2595597037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.